Retatrutide: Triple Receptor Agonism, Phase 2 Efficacy, Phase 3 Pending

The short version

Retatrutide (also called LY3437943) is an investigational metabolic peptide. It is a 39-amino-acid compound built on a GIP-based backbone, with a fatty-acid chain attached to extend its half-life to approximately six days, allowing once-weekly injection. Unlike prior metabolic agents that target one or two receptors, retatrutide engages three at once: GIP, GLP-1, and glucagon receptors ^[6].

In a 48-week Phase 2 obesity trial, the highest-dose group lost a mean 24.2% of body weight versus 2.1% with placebo ^[9]. A parallel substudy showed 82.4% relative reduction in liver fat at 24 weeks ^[8]. In a 36-week Phase 2 type 2 diabetes trial, HbA1c dropped by 2.02% and body weight by 16.94% at 36 weeks ^[10].

Retatrutide is not approved by any regulator. It remains in Phase 3 trials. No prescription or consumer version exists. All figures on this page come from clinical trials conducted under medical oversight — they describe study populations, not personal outcomes. No dose is listed here.

What it is

Retatrutide is a synthetic 39-amino-acid peptide built on a GIP-based sequence backbone, acylated at one position with a C20 fatty-diacid group. That acylation enables albumin binding, which extends the compound's plasma half-life to approximately six days and permits once-weekly subcutaneous dosing — a profile established in the Phase 1b first-in-human trial ^[11]. Molecular formula (free acid): C221H342N46O68.

It is classified as a GIP/GLP-1/glucagon receptor triple agonist. Three distinct receptor systems are engaged in a single molecule. That triple agonism is what distinguishes it mechanistically from dual agents and from single-agonist compounds in the same pharmacological class.

How it works

Retatrutide engages three receptor systems, and each contributes differently to the metabolic response:

• GLP-1 receptor (GLP-1R): Activating GLP-1R slows gastric emptying, reduces appetite, and augments glucose-dependent insulin secretion. This is the primary appetite-suppression arm.
• GIP receptor (GIPR): Retatrutide is approximately 8.9-fold more potent at GIPR than native GIP itself ^[7]. GIP synergizes with GLP-1 on insulin secretion and appears to reduce some of the GI side effects that limit pure GLP-1 agonism.
• Glucagon receptor (GCGR): Controlled glucagon receptor activation increases energy expenditure through thermogenic pathways and mobilizes stored fat. This is the mechanism believed to drive the thermogenic sensation reported in community use, and it also contributes to the liver-fat reduction observed in the MASLD substudy ^[8].

Cryo-EM structural work resolved retatrutide binding at each of the three receptors at near-atomic resolution (2.68-3.26 Å), confirming the simultaneous triple-receptor engagement and characterizing the distinct conformational loops the molecule adopts at each receptor ^[7]. The combination of GIP-mediated satiety augmentation, GLP-1-driven appetite suppression, and glucagon-driven energy expenditure is the proposed explanation for why weight loss in Phase 2 exceeded what prior single or dual agents produced.

What the research shows

Phase 1b first-in-human (2022). In 72 adults with type 2 diabetes, retatrutide established a ~6-day half-life consistent with once-weekly dosing. At the highest dose, placebo-adjusted weight loss was -8.96 kg over 12 weeks. Daily glucose fell by 2.8 mmol/L at 3 mg. Treatment-emergent adverse events in 63% were mostly GI in nature; no safety signals precluded advancement ^[11].

Phase 2 obesity trial (2023, N Engl J Med). 338 adults with obesity received once-weekly retatrutide across multiple dose levels or placebo for 48 weeks. At the highest dose (12 mg), mean body weight changed by -24.2% versus -2.1% with placebo. GI adverse events — nausea, vomiting, diarrhea, constipation — were the most common side effects and were dose-dependent. Heart rate increased in a dose-dependent pattern, peaking at approximately 24 weeks ^[9].

Phase 2 type 2 diabetes trial (2023, Lancet). 281 adults with T2D received retatrutide or placebo/active comparator for 36 weeks. The 12 mg group saw HbA1c fall by 2.02% (versus -0.01% placebo) at 24 weeks, and body weight fall by 16.94% (versus -3.00% placebo) at 36 weeks. Mild-to-moderate GI AEs appeared in 35%. No severe hypoglycemia or deaths ^[10].

Phase 2 MASLD substudy (2024, Nature Medicine). 98 participants with obesity or overweight and established metabolic liver disease (≥10% liver fat by MRI) received retatrutide for 48 weeks. At 12 mg at 24 weeks, relative liver fat reduction was -82.4%, with 86% of participants reaching a normal liver fat level below 5%. Reductions were sustained to 48 weeks (-86.0% at 12 mg) ^[8].

Structural pharmacology (2024, Cell Discovery). Cryo-EM structures of retatrutide bound to each of the three target receptors were resolved at near-atomic resolution, confirming the triple engagement model and mapping the relative potency: approximately 8.9× native GIP at GIPR, 0.4× native GLP-1 at GLP-1R, and 0.3× native glucagon at GCGR ^[7].

Metabolomics post-hoc (2026, J Clin Endocrinol Metab). Pooled lipidomics and metabolomics from Phase 2 obesity and T2D cohorts (n=282 + n=213) found that higher doses were associated with reductions in triglycerides and in insulin-resistance biomarkers (branched-chain amino acids, 2-hydroxybutyrate, urate) in a direction associated with reduced cardiovascular risk. Changes in a fatty-acid oxidation metabolite cluster mediated 23.2% of the weight-reduction response in non-T2D participants ^[12].

2025 review (Biomolecules). Synthesized Phase 1/2 data and characterized the triple-agonist pharmacology, characterizing the up-to-24% weight loss as a step-change relative to prior incretin monotherapies. Documents the ongoing Phase 3 TRIUMPH program ^[6].

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence): Research-use communities describe the most notable benefit as a near-total silencing of intrusive food thoughts — frequently called "food noise going quiet." Rapid and pronounced weight reduction is also frequently reported, with members describing faster scale movement than with other GLP-1-class compounds, consistent in direction with the trial data. Increased body warmth and mild thermogenic sensations — running warmer, sweating more easily — are commonly reported and attributed in community discussion to the glucagon receptor arm. An elevated resting heart rate, particularly in hours after administration, is also commonly noted, mapping to the dose-dependent heart-rate increases documented in Phase 2 ^[9]. Occasionally reported: improved mood, a lighter relationship with food, and reduced anxiety around eating. Concerns about lean-mass loss alongside fat mass are occasionally raised by community members who track body composition — a genuine research question addressed in the Phase 2 substudy data.

Frequently or commonly reported side effects include nausea (peaking 4-8 hours after injection and most prominent during the first weeks), sulfur burps attributed to slowed gastric motility, fatigue and low energy in the early weeks, and constipation. Occasionally reported: injection-site itch or mild local reaction, sleep disturbances. All of the above are unverified self-reports from research-use communities with no confirmed doses or clinical oversight.

Cautions from the trials and regulatory record:

• Not approved. Retatrutide is investigational only. No prescription product exists. Obtaining it outside a clinical trial means no verified identity, purity, or sterility of the injected substance. Independent analyses of similar gray-market peptides have found sequence truncations, racemized amino acids, or entirely different compounds. The FDA issued warning letters to retatrutide vendors in 2025 citing violations of the Federal Food, Drug, and Cosmetic Act ^[9][6].
• GI adverse events. In the Phase 2 obesity trial, nausea affected up to 45% at the highest dose and was the principal driver of an 18% discontinuation rate at that level. Without clinical oversight for dose escalation, the risk of severe GI events, dehydration, and electrolyte imbalance is unmanaged ^[9].
• Heart rate. Dose-dependent heart-rate increases of approximately 5-7 bpm at the highest doses, peaking around 24 weeks, were documented in Phase 2. The mechanism is glucagon receptor-mediated cardiac chronotropy via cAMP/PKA signaling. Long-term arrhythmia burden, MACE effects, and cardiac remodeling outcomes are still under study in dedicated cardiovascular outcome trials ^[9][6].
• Hypoglycemia risk with insulin or sulfonylureas. GLP-1 and GIP receptor agonism augments insulin secretion; in combination with existing insulin or sulfonylurea therapy, this can drive blood glucose below safe thresholds. Phase 2 diabetic participants on background insulin required insulin dose de-escalation during the trial ^[10][11].
• Lean-mass reduction. Phase 2 body-composition data confirmed retatrutide reduces lean mass in absolute terms alongside fat. The fat-to-lean loss ratio was more favorable than historic bariatric benchmarks, but absolute lean loss in rapid-weight-loss contexts is clinically meaningful, particularly for older individuals or those with sarcopenic risk ^[12].
• Long-term unknowns. TRIUMPH-1/2/3 and dedicated cardiovascular and kidney outcome trials are ongoing. No long-term outcomes data exist. Weight regain after discontinuation — documented with analogous GLP-1-class agents — is expected but uncharacterized for retatrutide specifically.

Where it fits in repair and metabolic research

Retatrutide is the metabolic lead on this desk. Where BPC-157 addresses repair through tissue-level angiogenesis in animal models and tesamorelin acts upstream via the growth-hormone axis to reduce visceral fat in a defined population, retatrutide targets metabolic dysfunction at the receptor level across three simultaneous pathways. Its Phase 2 data represent the most robust human clinical evidence of the three compounds here — and also the most fully enumerated risk profile. It is also the only one with no current regulatory approval of any kind. Phase 3 results will clarify whether its Phase 2 magnitude of effect holds at scale. See the comparison page for a structured overview of all three.